Roche’s Lunsumio VELO–Polivy combo moves closer to FDA decision after strong lymphoma trial results
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Full approval will depend on verification of clinical benefit in a confirmatory trial
Subscribe To Our Newsletter & Stay Updated